姓 名： 孟详喻
性 别：男
最高学位：博士
职 称：副教授
职 务：硕导
学科专业：药理学
办公室：医学部B506
实验室：医学实训中心A321、医学部S401
E-mail：mengxy_whu@163.com
研究方向：①膀胱癌的发病机制及精准诊疗 ②复杂疾病的遗传挖掘及药物发现
个人简介
孟详喻，湖北恩施人，土家族，农工党员，湖北省“楚天学者”
教育经历
2008.09 - 2015.06，武汉大学，临床医学七年制中法班
2012.09 - 2013.01，Université de Lorraine，访学
2014.10 - 2014.12，北海道大学，访学
2018.12 - 2022.10，Université Paris-Saclay，PhD，supported by INSERM 215K€
工作经历
2015.07 - 2018.06，武汉大学中南医院，研究实习员
2023.01 - 2024.03，湖北民族大学医学部，讲师
2024.04 - 至今，湖北民族大学医学部，副教授
学术兼职
湖北省生物信息学会理事
亚太生物医学免疫学会血液学专委会委员、湖北省医学生物免疫学会青年委员会委员
欧洲肿瘤内科学会ESMO会员、全法中国科技工作者协会会员
《临床内科杂志》通讯编委
Genomics, Proteomics & Bioinformatics青年编委
Phenomics青年编委
iMeta青年编委
Oncology and Translational Medicine青年编委
Med、Advanced Science、Journal of Advanced Research等数十本SCI期刊审稿人
论文、专著
以第一/共一/通讯作者在European Urology (3篇，1篇Cover)、Genome Medicine (1篇Feature)、Molecular Cancer、Advanced Science、Journal of Hematology & Oncology、Theranostics、Clinical Chemistry、Journal for ImmunoTherapy of Cancer、Advanced Healthcare Materials、Clinical and Translational Medicine 等高影响力期刊发表论文多篇。论文总引用>1,800，H-index 26。主编、参编专著5部。
科研教学项目
主持、参与省部级与国家级科研项目3项
参与教育部学位与研究生教育发展中心主题案例项目1项
主持省级重点实验平台开放课题多项
科研教学成果及奖励
中国国际“互联网+”大学生创新创业大赛国家级铜奖，2021
中国设备管理协会·第五届全国设备管理与技术创新成果二等奖，2022
全国大学生医学创新大赛暨“一带一路”国际竞赛省级三等奖，2025
外语水平
英（TOEFL C1）、法（TEF B2）、日（JLPT N1）
主要论文、专著成果列表
Xiang-Yu Meng*. GM-CSF+ Th: a central player in autoimmunity. Theranostics. 2025, 15(18):9944-9968. (IF: 13.3，中科院1区top).
Xiang-Yu Meng*. Convergent and divergent mitochondrial pathways as causal drivers and therapeutic targets in neurological disorders. Curr Issues Mol Biol. 2025, 47(8): 636. (IF: 3.0，中科院3区).
Xiang-Yu Meng#,*. Gene and pathway analysis of genome-wide genetic associations of bladder cancer. Curr Urol. 2025, 19(5):321-330. (IF: 1.3，中科院4区; Cover).
Xiang-Yu Meng#. Cyclic enrichment of urinary exosomes using a MOF-on-MOF-based asymmetric impinging streams chip for bladder cancer diagnosis and prognosis prediction. Adv Healthc Mater. 2025, 14(14):e2500848. (IF: 9.6，中科院2区).
Xiang-Yu Meng*. SysNatMed: rational natural medicine discovery by systems genetics. Front Pharmacol. 2025:1496061 (IF: 4.8, 中科院3区).
Xiang-Yu Meng*. Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications. Mol Cancer. 2024:265 (IF: 33.9, 中科院1区top)
Xiang-Yu Meng#. Machine learning-based detection of bladder cancer by urine cfDNA fragmentation hotspots that capture cancer-associated molecular features. Clin Chem. 2024, 70(12):1463-1473 (IF: 6.3, ADLM official journal, 中科院小类1区).
Xiang-Yu Meng*. Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns. Adv Sci (Weinh). 2024:e2308243 (IF: 14.1, 中科院1区 top).
Xiang-Yu Meng#,*. Sex bias in FGFR3 somatic mutations in bladder cancer. Oncol Trans Med. 2024, 10(5): 252-256 (CSTPCD).
Xiang-Yu Meng*. Single-cell analyses reveal evolution mimicry during the specification of breast cancer subtype. Theranostics. 2024, 14(8):3104-3126 (IF: 13.3, 中科院1 区top).
Xiang-Yu Meng*. The underexplored role of APOBEC3 enzymes in autoimmune diseases. Rheumatology (Oxford). 2024, 63(6):e166-e167 (IF: 4.4, 中科院2区).
Xiang-Yu Meng*. Landscape of urine biomarkers for bladder cancer: molecular function, cell-of-origin, and bibliometric trend. Oncol Trans Med. 2024, 10(3):132-142 (CSTPCD).
Xiang-Yu Meng#,*. Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed. Epigenomics. 2023, 15(22):1175-1178 (IF: 2.6, 中科院4区).
Xiang-Yu Meng#,*. Historical pathogen-driven selection may contribute to contemporary ethnic difference in bladder cancer susceptibility. Bladder Cancer. 2023, 9(3): 211-216 (IF: 1.2, 中科院4区; BCAN official journal)
Xiang-Yu Meng#,*. Comments on “Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer”. Int J Cancer. 2023, 153(8):1543-1544 (IF: 4.7, 中科院2区).
Xiang-Yu Meng#,*. NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors. J Immunother Cancer. 2023, 11(6):e007255 (IF: 10.6, 中科院1区 top).
Xiang-Yu Meng*. The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer. J Transl Med. 2023, 21(1):298 (IF: 7.5, 中科院2 区top).
Xiang-Yu Meng#,*. “Paradoxical neoantigenic mutations”: not simply a driver vs passenger dualism. Br J Cancer. 2023, 129(1):1-2 (IF: 6.8, 中科院2 区top).
Xiang-Yu Meng#. FGFR3 mutational activation can induce luminal-like papillary bladder tumor formation and favors a male sex bias. Eur Urol. 2023, 83(1):70-81 (IF: 25.2, 中科院1 区top).
Xiang-Yu Meng*. Dynamic gene screening enabled identification of a 10-gene panel for early detection and progression assessment of gastric cancer. Comput Struct Biotechnol J. 2022, 21:677-687. (IF: 4.1, 中科院3区)
Xiang-Yu Meng*. Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer. J Hematol Oncol. 2022, 15(1):19 (IF: 40.4, 中科院1区 top).
Xiang-Yu Meng#,*. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. Genome Med. 2020, 12(1):85 (IF: 11.2, 中科院1区 top; Feature).
Xiang-Yu Meng*. ΔNp63 drives epithelial differentiation in glioma. Clin Transl Med. 2020, 10(4):e165 (IF: 6.8, 中科院2区 top).
Xiang-Yu Meng#. Estimation and projection about the standardized prevalence of osteoporosis in mainland China. Calcif Tissue Int. 2020, 106(2):131-146 (IF: 3.2, 中科院3区).
Xiang-Yu Meng#. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend's Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated Mutagenesis as, a Likely Cause of FGFR3 S249C Mutation Over-representation in Bladder Cancer. Eur Urol 2019, 76:9-13. Eur Urol. 2020, 77(1):e24-e25 (IF: 25.2, 中科院1区 top).
Xiang-Yu Meng#. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur Urol. 2019, 76(1):9-13 (IF: 25.2, 中科院1区 top; Cover).
Xiang-Yu Meng#. The role of COL5A2 in patients with muscle-invasive bladder cancer: a bioinformatics analysis of public datasets involving 787 subjects and 29 cell lines. Front Oncol. 2019, 8:659 (IF: 3.3, 中科院3区).
Xiang-Yu Meng*. Long-term efficacy of maintenance therapy for multiple myeloma: A quantitative synthesis of 22 randomized controlled trials. Front Pharmacol. 2018, 9:430 (IF: 4.8, 中科院3区).
Xiang-Yu Meng*. Bortezomib, thalidomide, and dexamethasone (VTD) induction results in better overall survival than adriamycin, thalidomide, and dexamethasone (ATD) induction in previously untreated myeloma patients eligible for transplants. Acta Haematol. 2017, 137(4):207-208 (IF: 1.1, 中科院4区).
Xiang-Yu Meng*. La relation entre la récurrence de la tumeur et les polymorphismes génétiques de hGPX1 et NRAMP1 chez les patients atteints du cancer superficiel de la vessie: une méta-analyse. Pan Afr Med J. 2017, 27: 270 (in French).
Xiang-Yu Meng*. Baicalein suppresses the proliferation of acute T-lymphoblastic leukemia Jurkat cells by inhibiting the Wnt/β-catenin signaling. Ann Hematol. 2016, 95(11):1787-93 (IF: 2.4, 中科院3区).
《DK人体百科（涂色版）》，2019，北京科学技术出版社，主译
《人体筋膜系统功能学图谱》，2017，北京科学技术出版社，副主译
《应用STATA做Meta分析》，2016，中国协和医科大学出版社，编者
《循证临床实践指南的研发与评价》，2016，中国协和医科大学出版社，编者
《R与Meta分析》，2016，军事医学科学出版社，编者